Andrew Shaw

415 total citations
21 papers, 243 citations indexed

About

Andrew Shaw is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Andrew Shaw has authored 21 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Immunology. Recurrent topics in Andrew Shaw's work include Biosimilars and Bioanalytical Methods (5 papers), HER2/EGFR in Cancer Research (4 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Andrew Shaw is often cited by papers focused on Biosimilars and Bioanalytical Methods (5 papers), HER2/EGFR in Cancer Research (4 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Andrew Shaw collaborates with scholars based in United States, India and Germany. Andrew Shaw's co-authors include Stephen A. Kempson, G.V. Marinetti, William T. Jackson, Max Schlamowitz, Abhijit Barve, Cornelius F. Waller, Michael R. Franklin, Charles Lindamood, Raymond E. Galinsky and Stephan Ortiz and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Andrew Shaw

20 papers receiving 233 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Shaw United States 10 77 71 44 42 30 21 243
Charles A. Reidy United States 9 122 1.6× 54 0.8× 45 1.0× 15 0.4× 17 0.6× 13 338
T Okayasu Japan 9 73 0.9× 64 0.9× 87 2.0× 23 0.5× 18 0.6× 35 332
Jatinder Singh United States 13 190 2.5× 125 1.8× 46 1.0× 24 0.6× 16 0.5× 37 430
Raffaele Raucci Italy 12 144 1.9× 75 1.1× 52 1.2× 14 0.3× 14 0.5× 17 352
Nicholas Hadjokas United States 11 127 1.6× 101 1.4× 91 2.1× 68 1.6× 15 0.5× 18 362
Elyes Dahmane United States 7 102 1.3× 99 1.4× 35 0.8× 12 0.3× 57 1.9× 14 321
Gaëlle Lenglet France 12 192 2.5× 41 0.6× 31 0.7× 23 0.5× 8 0.3× 23 425
Qingqing Wang China 11 112 1.5× 36 0.5× 28 0.6× 69 1.6× 11 0.4× 27 296
Yuchen Jiang China 10 173 2.2× 49 0.7× 55 1.3× 56 1.3× 10 0.3× 33 324

Countries citing papers authored by Andrew Shaw

Since Specialization
Citations

This map shows the geographic impact of Andrew Shaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Shaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Shaw more than expected).

Fields of papers citing papers by Andrew Shaw

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Shaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Shaw. The network helps show where Andrew Shaw may publish in the future.

Co-authorship network of co-authors of Andrew Shaw

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Shaw. A scholar is included among the top collaborators of Andrew Shaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Shaw. Andrew Shaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shaw, Andrew, Jeffery D. Steketee, Anna N. Bukiya, & Alex M. Dopico. (2024). Toluene is a cerebral artery constrictor acting via BK channels. Neuropharmacology. 266. 110272–110272.
2.
3.
Shaw, Andrew, et al.. (2023). Progesterone activation of β1-containing BK channels involves two binding sites. Nature Communications. 14(1). 7248–7248. 3 indexed citations
4.
Hummel, Matthew A., et al.. (2021). A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab. Journal of Cancer Research and Clinical Oncology. 148(2). 487–496. 9 indexed citations
5.
Waller, Cornelius F., Renger G. Tiessen, Andrew Shaw, et al.. (2018). A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. Journal of Cancer Research and Clinical Oncology. 144(6). 1087–1095. 17 indexed citations
6.
Shaw, Andrew, et al.. (2018). Connexin 43 Plays a Role in Pulmonary Vascular Reactivity in Mice. International Journal of Molecular Sciences. 19(7). 1891–1891. 16 indexed citations
7.
Waller, Cornelius F., Andrew Shaw, Rajiv Sharma, et al.. (2018). A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL‐1401O vs. EU‐trastuzumab and US‐trastuzumab. British Journal of Clinical Pharmacology. 84(10). 2336–2343. 20 indexed citations
8.
Socinski, Mark A., et al.. (2017). A bioequivalence study of proposed bevacizumab biosimilar, MYL-1402O (A) vs EU-Avastin (B) and US-Avastin (C).. Journal of Clinical Oncology. 35(15_suppl). e14034–e14034. 3 indexed citations
9.
Waller, Cornelius F., et al.. (2017). A pharmacokinetics (PK) bioequivalence trial of proposed trastuzumab biosimilar, Myl-1401O (A) vs EU-Herceptin (B) and US-Herceptin (C). European Journal of Cancer. 72. S40–S41. 5 indexed citations
10.
Waller, Cornelius F., Renger G. Tiessen, Andrew Shaw, et al.. (2016). A pharmacokinetics and pharmacodynamics equivalence trial of proposed pegfilgrastim biosimilar, MYL-1401H vs EU neulasta® and US neulasta®. Annals of Oncology. 27. vi503–vi503. 3 indexed citations
11.
Waller, Cornelius F., et al.. (2016). A pharmacokinetics (PK) bioequivalence trial of proposed trastuzumab biosimilar, Myl-1401O (A) vs EU-Herceptin (B) and US-Herceptin (C).. Journal of Clinical Oncology. 34(15_suppl). 583–583. 5 indexed citations
12.
Lindamood, Charles, et al.. (2010). Effects of Commonly Administered Agents and Genetics on Nebivolol Pharmacokinetics: Drug-Drug Interaction Studies. The Journal of Clinical Pharmacology. 51(4). 575–585. 25 indexed citations
13.
Shaw, Andrew, Stephen D. Hall, Michael R. Franklin, & Raymond E. Galinsky. (2002). The Influence of l-Glutamine on the Depression of Hepatic Cytochrome P450 Activity in Male Rats Caused by Total Parenteral Nutrition. Drug Metabolism and Disposition. 30(2). 177–182. 18 indexed citations
14.
Veale, Chris A., David Aharony, Debra L. Banville, et al.. (2000). The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. part 1. Bioorganic & Medicinal Chemistry Letters. 10(17). 1949–1952. 28 indexed citations
15.
Delport, Rhena, et al.. (1992). Relationship between maternal and neonatal vitamin B6 metabolism: perspectives from enzyme studies.. PubMed. 7(4). 260–4; discussion 264. 2 indexed citations
16.
Caputo, C.B., et al.. (1988). Protease inhibitors decrease rabbit cartilage degradation after meniscectomy. Journal of Orthopaedic Research®. 6(1). 103–108. 11 indexed citations
17.
Caputo, C.B., et al.. (1987). Proteoglycan degradation by a chondrocyte metalloprotease. Biochemical Pharmacology. 36(7). 995–1002. 13 indexed citations
18.
Kempson, Stephen A., G.V. Marinetti, & Andrew Shaw. (1978). Hormone action at the membrane level VII. Stimulation of dihydroalprenolol binding to beta-adrenergic receptors in isolated rat heart ventricle slices by triiodothyronine and thyroxine. Biochimica et Biophysica Acta (BBA) - General Subjects. 540(2). 320–329. 38 indexed citations
19.
Schlamowitz, Max, Andrew Shaw, & William T. Jackson. (1969). Limitations of he Dixon plot for ascertaining naure of enzyme inhibition.. PubMed. 27(2). 483–8. 6 indexed citations
20.
Schlamowitz, Max, Andrew Shaw, & William T. Jackson. (1968). The Nature of the Binding of Inhibitors to Pepsin and the Kinetics of Inhibited Peptic Hydrolysis of N-Acetyl-L-phenylalanyl-L-tyrosine. Journal of Biological Chemistry. 243(10). 2821–2828. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charles A. Reidy Breakdown of academic impact, for papers by T Okayasu Breakdown of academic impact, for papers by Jatinder Singh Breakdown of academic impact, for papers by Raffaele Raucci Breakdown of academic impact, for papers by Nicholas Hadjokas Breakdown of academic impact, for papers by Elyes Dahmane Breakdown of academic impact, for papers by Gaëlle Lenglet Breakdown of academic impact, for papers by Qingqing Wang Breakdown of academic impact, for papers by Yuchen Jiang
Rankless by CCL
2026